 |
449 Diseases |  |
58 Trials |
|
58 Trials |  |
3605 News |  |
| «12...13141516171819202122232425 |
- Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Combination therapy, Metastases: Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer (clinicaltrials.gov) - Apr 9, 2012
P2, N=48, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting
- | Leukine (sargramostim) / Partner Therap
Trial completion, Pneumococcal vaccines, Metastases: Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients (clinicaltrials.gov) - Apr 5, 2012
P2, N=39, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Terminated --> Completed
- | Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's, Herceptin (trastuzumab) / Roche
New P2 trial: Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax (clinicaltrials.gov) - Apr 2, 2012
P2, N=300, Recruiting, Sponsor: Jarrod P. Holmes, MD, FACP
- Leukine (sargramostim) / Partner Therap
Enrollment change, Metastases: Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy (clinicaltrials.gov) - Mar 27, 2012
P2, N=21, Completed, Sponsor: University of Washington
Terminated --> Completed N=30 --> 21
- Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy (clinicaltrials.gov) - Mar 27, 2012
P2, N=21, Completed, Sponsor: University of Washington
N=30 --> 21 Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Enrollment closed, Post-transplantation: Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation (clinicaltrials.gov) - Mar 25, 2012
P1, N=40, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Active, not recruiting --> Completed Completed --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap
Trial termination, Metastases: Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer (clinicaltrials.gov) - Mar 19, 2012
P1/2, N=37, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting Completed --> Terminated; The study was closed to accrual due to very poor enrollment.
- Bexxar (iodine I 131 tositumomab) / GSK
Enrollment closed: Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 14, 2012
P2, N=25, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Completed --> Terminated; The study was closed to accrual due to very poor enrollment. Completed --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap
New P2 trial: Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Feb 29, 2012
P2, N=8, Terminated, Sponsor: M.D. Anderson Cancer Center
- Leukine (sargramostim) / Partner Therap
Trial completion: Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 27, 2012
P1/2, N=69, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting Active, not recruiting --> Completed
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment closed: Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - Feb 18, 2012
P2, N=70, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap
New P1 trial: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Feb 16, 2012
P1, N=36, Recruiting, Sponsor: Roswell Park Cancer Institute
- | Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
New P2 trial: Ipilimumab and GMCSF Immunotherapy for Prostate Cancer (clinicaltrials.gov) - Feb 8, 2012
P2, N=54, Not yet recruiting, Sponsor: Lawrence Fong
- ||||| Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
New P1/2 trial: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL (clinicaltrials.gov) - Feb 2, 2012
P1/2, N=60, Completed, Sponsor: Fernando Cabanillas
- AST-301 / University of Washington, Aston Sci., EpiThany
Enrollment change: Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer (clinicaltrials.gov) - Jan 23, 2012
P2, N=38, Active, not recruiting, Sponsor: University of Washington
Recruiting --> Active, not recruiting N=52 --> 38
- Leukine (sargramostim) / Partner Therap
New P2 trial: FAMPAP: Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP) (clinicaltrials.gov) - Jan 16, 2012
P2, N=2, Enrolling by invitation, Sponsor: Children's Hospital Medical Center, Cincinnati
- daunorubicin / Generic mfg.
Enrollment change: S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 12, 2012
P2, N=71, Completed, Sponsor: Southwest Oncology Group
N=52 --> 38 N=55 --> 71
- daunorubicin / Generic mfg., cyclosporine / Generic mfg.
Trial completion: S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 12, 2012
P2, N=69, Completed, Sponsor: Southwest Oncology Group
N=55 --> 71 Active, not recruiting --> Completed
- daunorubicin / Generic mfg.
Trial completion: S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 12, 2012
P2, N=71, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Amdray (valspodar) / Novartis
Trial completion: S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 12, 2012
P2, N=55, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Enrollment open: PROPEL: Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD) (clinicaltrials.gov) - Jan 8, 2012
P=N/A, N=240, Recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Leukine (sargramostim) / Partner Therap
New P4 trial, Immunomodulating: GM-CSF for Immunomodulation Following Trauma (GIFT) Study (clinicaltrials.gov) - Dec 18, 2011
P4, N=200, Recruiting, Sponsor: Mark Hall
- Promune (agatolimod) / Pfizer, Leukine (sargramostim) / Partner Therap
Trial completion, Surgery, Metastases: Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 13, 2011
P=N/A, N=20, Completed, Sponsor: University of Pittsburgh
Not yet recruiting --> Recruiting Recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / Ono Pharma, BMS
Biomarker, Metastases: Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim (clinicaltrials.gov) - Dec 7, 2011
P=N/A, N=270, Not yet recruiting, Sponsor: Eastern Cooperative Oncology Group
- ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Trial completion, Metastases: Vaccine and Antibody Treatment of Prostate Cancer (clinicaltrials.gov) - Dec 1, 2011
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Completed
- |||||||||| Rintega (rindopepimut) / Celldex
New P3 trial: Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Nov 27, 2011
P3, N=700, Recruiting, Sponsor: Celldex Therapeutics
- || NeuVax (nelipepimut-S) / Dr. Reddy's
New P3 trial: PRESENT: Efficacy and Safety Study of NeuVax (clinicaltrials.gov) - Nov 22, 2011
P3, N=700, Recruiting, Sponsor: Galena Biopharma, Inc.
- Campath (alemtuzumab) / Sanofi
Trial termination: Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma (clinicaltrials.gov) - Nov 3, 2011
P2, N=27, Terminated, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Completed --> Terminated; Slow Accrual.
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment change, Metastases: Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Oct 24, 2011
P2, N=20, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
Completed --> Terminated; Slow Accrual. N=33 --> 20
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion, Metastases: Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Oct 24, 2011
P2, N=20, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
N=33 --> 20 Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Trial completion, IO biomarker: Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Oct 13, 2011
P2, N=43, Completed, Sponsor: AIDS Malignancy Clinical Trials Consortium
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Enrollment closed, Combination therapy: Decitabine, Vaccine Therapy, and Doxorubicin Hydrochloride Liposome in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Oct 12, 2011
P1, N=18, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap
Enrollment closed: Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer (clinicaltrials.gov) - Sep 1, 2011
P2, N=8, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Targretin oral (bexarotene oral) / ReXceptor, Leukine (sargramostim) / Partner Therap
Enrollment closed: Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 23, 2011
P2, N=26, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Leukine (sargramostim) / Partner Therap
Enrollment change, Pneumococcal vaccines, Metastases: Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients (clinicaltrials.gov) - Aug 9, 2011
P2, N=39, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting N=101 --> 39